1. Home
  2. XGN vs RCEL Comparison

XGN vs RCEL Comparison

Compare XGN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XGN
  • RCEL
  • Stock Information
  • Founded
  • XGN 2002
  • RCEL N/A
  • Country
  • XGN United States
  • RCEL United States
  • Employees
  • XGN N/A
  • RCEL N/A
  • Industry
  • XGN Medical Specialities
  • RCEL Medical/Dental Instruments
  • Sector
  • XGN Health Care
  • RCEL Health Care
  • Exchange
  • XGN Nasdaq
  • RCEL Nasdaq
  • Market Cap
  • XGN 138.3M
  • RCEL 161.5M
  • IPO Year
  • XGN 2019
  • RCEL N/A
  • Fundamental
  • Price
  • XGN $7.23
  • RCEL $5.19
  • Analyst Decision
  • XGN Strong Buy
  • RCEL Strong Buy
  • Analyst Count
  • XGN 2
  • RCEL 4
  • Target Price
  • XGN $7.50
  • RCEL $16.50
  • AVG Volume (30 Days)
  • XGN 236.6K
  • RCEL 293.0K
  • Earning Date
  • XGN 08-04-2025
  • RCEL 08-07-2025
  • Dividend Yield
  • XGN N/A
  • RCEL N/A
  • EPS Growth
  • XGN N/A
  • RCEL N/A
  • EPS
  • XGN N/A
  • RCEL N/A
  • Revenue
  • XGN $56,724,000.00
  • RCEL $71,661,000.00
  • Revenue This Year
  • XGN $19.39
  • RCEL $57.29
  • Revenue Next Year
  • XGN $13.27
  • RCEL $28.07
  • P/E Ratio
  • XGN N/A
  • RCEL N/A
  • Revenue Growth
  • XGN 1.78
  • RCEL 41.35
  • 52 Week Low
  • XGN $1.71
  • RCEL $5.10
  • 52 Week High
  • XGN $7.95
  • RCEL $14.16
  • Technical
  • Relative Strength Index (RSI)
  • XGN 56.74
  • RCEL 29.07
  • Support Level
  • XGN $7.10
  • RCEL $5.10
  • Resistance Level
  • XGN $7.95
  • RCEL $6.33
  • Average True Range (ATR)
  • XGN 0.51
  • RCEL 0.32
  • MACD
  • XGN -0.04
  • RCEL 0.02
  • Stochastic Oscillator
  • XGN 46.67
  • RCEL 6.10

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: